ClinicalTrials.gg
RecruitingNCT06380842Updated Jul 10, 2026

Organ Dysfunction Change in Acute Necrotizing Pancreatitis Patients With Sepsis After Open Necrosectomy

An observational study in Necrotizing Pancreatitis, sponsored by Chunling Jiang. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Chunling Jiang · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Pancreatitis, Acute Necrotizing with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Pancreatitis, Acute Necrotizing · China.

Started
2024
the only one that year
Observational
3 of 17
2 open now
Registered
14th of 17
by date
Lead sponsor
1 of 17
Chunling Jiang

Among the 17 studies in Pancreatitis, Acute Necrotizing with a site in China, this one is the only one that started in 2024, is one of 3 observational ones, and was the 14th registered.

Pancreatitis, Acute Necrotizing

75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.

Browse Pancreatitis, Acute Necrotizing studies →

Open to participants now

6 of the 17 studies in Pancreatitis, Acute Necrotizing with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Pancreatitis, Acute Necrotizing studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pancreatitis, Acute Necrotizing with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to characterize organ dysfunction change in acute necrotizing pancreatitis patients with sepsis after open necrosectomy.

Read the detailed description

Before surgery, study participants will be asked questions about age, gender, education level, etc. Study participants will also be questioned regarding pancreatic symptoms, as measured on the Patient-Reported Outcome Scale in Acute Pancreatitis (including pain, abdominal distention, eating, bowel movements, nausea and vomiting, thirst, and weakness). Organ dysfunction was defined according to the Sequential Organ Failure Assessment (SOFA) score. The SOFA score will be measured at preoperative (T1), postoperative day 1 (T2), postoperative day 3 (T3), postoperative day 7, or at hospital discharge, whichever comes first (T4). Participants who provide optional consent for biospecimen collection will have peripheral venous blood samples (5-10 mL) collected at predefined preoperative and postoperative time points. Samples will be processed and stored for biomarker analyses, including inflammatory marker measurement, metabolomic profiling, and other exploratory analyses related to the objectives of this study. Following discharge from the hospital, study participants will be contacted at 1 month, 3 months, 6 months, and 1 year after surgery, and asked to complete a survey about their pancreatic symptoms and survival status after surgery.

03

Conditions studied

  • Necrotizing Pancreatitis

Keywords

  • Acute Necrotizing Pancreatitis
  • sepsis
  • organ dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Acute necrotizing pancreatitis Patients with sepsis scheduled for open necrosectomy will be invited to participate in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients 18 years or older
  2. Diagnosis of Acute pancreatitis according to the revised Atlanta classification, requires two of the following three criteria: (A) typical abdominal pain, (B) an increase in serum amylase or lipase levels higher than three times the upper limit of normality, and (C) signs of AP in imaging
  3. Patients with confirmed or suspected infected pancreatic or peripancreatic necrosis were scheduled for open necrosectomy
  4. Meet Sepsis-3 criteria

Exclusion criteria

Exclusion Criteria:

  1. Patients refuse to participate
  2. Patients undergo repeat surgery on the same site
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pancreatitis with sepsis patients' organ dysfunction progression after open necrosectomy

    Acute necrotizing pancreatitis patients with sepsis undergoing open necrosectomy will be measured SOFA scores at a special time point to characterize organ dysfunction experience profiles.

    Other: Necrotizing Pancreatitis patients' organ dysfunction progression

Interventions

  • OtherNecrotizing Pancreatitis patients' organ dysfunction progression

    Study the dynamic nature of organ dysfunction

06

What researchers measure

Primary outcomes

  1. Measure organ dysfunction change after open necrosectomy with respect to time

    Organ dysfunction will be measured using sequential organ failure assessment score scale. The scores range from 0 (normal) to 4(most abnormal) for each organ, with higher scores indicating worse health status

    Time frame: up to postoperative day 7, or at hospital discharge, whichever comes first

Secondary outcomes

  1. incidence of a composite of major complications

    Major complications were defined as new-onset organ failure (ie, cardiovascular, pulmonary, or renal)

    Time frame: up to postoperative day 28

  2. Incidence of ICU mortality

    Death occurred in ICU

    Time frame: through study completion, an average of 1year

  3. Incidence of hospital mortality

    Death occurred in hospital

    Time frame: through study completion, an average of 1 year

  4. Incidence of 28-day mortality

    Death occurred within 28-day after surgery

    Time frame: through study completion, an average of 1 year

  5. Incidence of one year mortality

    Death occurred within one year after surgery

    Time frame: through study completion, an average of 1 year

  6. ICU length of hospital stay

    Determined by the number of days from ICU admittance to discharge from ICU

    Time frame: through study completion, an average of 1 year

  7. Length of hospital stay

    Determined by the number of days from admittance to discharge

    Time frame: through study completion,an average of 1 year

  8. The pancreatic symptoms score

    Pancreatic symptom scores will be measured at preoperative, postoperative day 1, day 2, day 3, day 7, or at hospital discharge, whichever comes first, at 1 month, 3 months, 6 months, and 1 year postoperatively. Both were measured using the Patient-Reported Outcome Scale, which ranges from 0 to 10 for each symptom; The overall range is from 0 to 70, with higher scores indicating higher symptom intensity.

    Time frame: up to 1 year

  9. The levels of inflammatory factor CRP

    Peripheral blood CRP

    Time frame: preoperative, postoperative day 1, day 3 and day 7 or at hospital discharge, whichever came first.

  10. The levels of inflammatory cytokines IL-6

    cytokines IL-6

    Time frame: preoperative, postoperative day 1, day 3 and day 7 or at hospital discharge, whichever came first.

  11. The levels of inflammatory procalcitonin

    procalcitonin was measured at preoperative, postoperative day 1, day 3 and day 7 or at hospital discharge, whichever came first.

    Time frame: preoperative, postoperative day 1, day 3 and day 7 or at hospital discharge, whichever came first.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Apr 24, 2024
StartActual
Jun 15, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06380842
Lead sponsor
Chunling Jiang
Responsible party
Chunling Jiang (Professor, West China Hospital) — Sponsor-investigator
First posted
Apr 24, 2024
Start date
Jun 15, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 10, 2026

Study contacts

Chunling Jiang, PhD
Contact
jiangchunling@scu.edu.cn
18980601096
Qian Li, PhD
Contact
jiangchunling@scu.edu.cn
18980601096
Fengming Luo, PhD
principal investigator · West China Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion